J&J subpoenaed for products sold to Omnicare
Executive Summary
J&J is responding to a subpoena for eight products sold to Omnicare, the company says in its 10-Q filing. The company reported receiving the subpoena from the U.S. Attorney's office in Massachusetts on Sept. 26. In July, J&J received a subpoena related to the sales and marketing of its congestive heart failure drug Natrecor (nesiritide). Omnicare broadened its long-term care pharmacy practice and specialty pharmaceutical distribution through the acquisition of NeighborCare and RxCrossroads in July (1"The Pink Sheet" July 11, 2005, p. 16)...
You may also be interested in...
Omnicare Bulks Up And Branches Out With NeighborCare, RxCrossroads Deals
Omnicare will broaden its long-term care pharmacy practice and gain a specialty pharmaceutical distribution division through the acquisitions of NeighborCare and RxCrossroads in deals valued at a combined $2 bil
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.